Infections
Conditions
Interventions
Observation group:None
Sponsors
Zhongda Hospital, Southeast University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Entry Criteria: 1) Age 18-85 years old; 2) Male or female; 3) Patients with severe infections (refer to 2016 sepsis 3.0 guidelines for criteria defining severe infections); 4) Primary infection site specimen confirmed or proposed by bacterial culture for at least one carbapenem-resistant gram-negative pathogen (including but not limited to carbapenem-resistant Enterobacteriaceae and/or Pseudomonas aeruginosa) that is susceptible to ceftazidime/avibactam; 5) Patients receiving continuous renal replacement therapy on the day of therapeutic drug monitoring 6) Sufficient samples of respiratory secretions, blood, and peritoneal fluid can be obtained for bacterial culture and drug sensitivity testing within 48 hours prior to the first dose; 7) Received ceftazidime avibactam continuously for = 72 hours; 8) Those who understand the compliance with the study procedures and methods, participate in the study voluntarily, and sign a written informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1) Patients who have not undergone blood concentration monitoring of ceftazidime/avibactam during treatment; 2) Patients with a history of severe allergy, hypersensitivity to ceftazidime/avibactam API or other components of the formulation; 3) Serious illness or expected survival of no more than 48 hours; 4) Pregnant (positive urine or serum ß-hCG test prior to randomization) or breastfeeding females; 5) other conditions that, in the opinion of the investigator, make enrollment inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PTA;Microbial clearance;28-day mortality rate; | — |
Countries
China
Contacts
Public ContactLinlin Hu
Zhongda Hospital, Southeast University
Outcome results
None listed